Weifang Ruze New Material Co., Ltd.

 

Your Aspiration is Our Commitment

Home
Products
About Us
Factory Tour
Quality Control
Contact Us
Request A Quote
Home ProductsAntineoplastic Drugs

99% Campaign Production Sparsentan Intermediates Cas 254746-77-5

Ruze supply good service, thanks.

—— Gaurav

I'm Online Chat Now

99% Campaign Production Sparsentan Intermediates Cas 254746-77-5

China 99% Campaign Production Sparsentan Intermediates Cas 254746-77-5 supplier
99% Campaign Production Sparsentan Intermediates Cas 254746-77-5 supplier 99% Campaign Production Sparsentan Intermediates Cas 254746-77-5 supplier

Large Image :  99% Campaign Production Sparsentan Intermediates Cas 254746-77-5

Product Details:

Place of Origin: Weifang,China
Brand Name: Ruze
Certification: COA MSDS
Model Number: 254746-77-5

Payment & Shipping Terms:

Minimum Order Quantity: Negotiable
Price: Negotiable
Packaging Details: durm
Delivery Time: 5-7 work days
Payment Terms: L/C, T/T, Western Union, MoneyGram
Supply Ability: 1000kg/week
Contact Now
Detailed Product Description
CAS: 254746-77-5 MF: C15H21BN2O7S
MW: 384.21244 Color: White Powder

 

Advantage of our API-CAS 254746-77-5   Sparsentan Intermediates

 

1. High purity

2. Consistent quality for Lorlatinib

3. Competitive price

4. Fast Shipping for Lorlatinib

 

99% Campaign Production Sparsentan Intermediates Cas 254746-77-5

SPARSENTAN

Sparsentan is a novel small-molecule candidate in Phase 3 development for the treatment of focal segmental glomerulosclerosis (FSGS) , a serious kidney disorder that often leads to end-stage renal disease (ESRD). The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have granted sparsentan orphan drug designation for FSGS. Retrophin also is advancing sparsentan for the treatment of immunoglobulin A nephropathy (IgAN) , or Berger’s disease, which also can lead to ESRD. Retrophin is examining the ability of sparsentan to slow the decline of kidney function in patients with FSGS and IgAN.

PATIENT NEED

FSGS is characterized by proteinuria, protein found in the urine due to a breakdown of the normal filtration mechanism in the kidney. Most often, the cause of the disorder is unknown, or “idiopathic”, but it can also be genetic. Less frequently, FSGS is associated with other conditions such as kidney defects from birth (dysplasia), urine backing up into kidneys (kidney reflux), obesity, sleep apnea, viruses, blood disorders and autoimmune disorders. There are no medications approved specifically for the treatment of FSGS. Learn more about FSGS .

IgAN , or Berger’s disease, is estimated to affect more than 100,000 people in the United States and greater numbers in Europe and Asia. The disease is caused by deposits of immunoglobulin A (IgA) in the kidney, which leads to hematuria (blood in the urine), proteinuria (protein in the urine) and progressive kidney failure. There is no indicated treatment for IgAN. Learn more about IgAN .

OUR APPROACH

Sparsentan is a single molecule designed to be a dual endothelin receptor type A (ETA) and angiotensin II receptor type 1 (AT1) antagonist. Our investigational approach is to attempt to reduce proteinuria, a characteristic marker of kidney injury in both FSGS and IgAN, with sparsentan. Lowering proteinuria levels is associated with better outcomes.

CLINICAL TRIALS

Sparsentan for FSGS

After completing the Phase 2 DUET Study, Retrophin initiated a global pivotal Phase 3 clinical trial in 2018 to support potential approval of sparsentan for patients with FSGS in the U.S. and Europe. The DUPLEX Study protocol provides for an unblinded analysis of at least 190 patients performed after 36 weeks of treatment to evaluate the surrogate efficacy endpoint – the proportion of patients achieving modified partial remission of proteinuria. The data from this analysis are expected to serve as the basis for submission of a New Drug Application under the Subpart H accelerated approval pathway in the U.S. and Conditional Marketing Authorization in Europe. Top-line efficacy data from the 36-week interim efficacy endpoint are expected in the first quarter of 2021. The confirmatory endpoint of the DUPLEX Study is the slope of eGFR assessed from week 6 to week 108 at the final analysis.

Sparsentan for IgAN

In 2018, Retrophin also initiated the PROTECT Study, a global pivotal Phase 3 clinical trial evaluating the safety and efficacy of sparsentan in patients with IgAN. The primary efficacy endpoint of the PROTECT Study is the change in proteinuria from baseline after 36 weeks of treatment. The study is expected to support submission of a New Drug Application under Subpart H accelerated approval pathway in the U.S., as well as an application for Conditional Marketing Authorization in Europe. Top-line efficacy data from the 36-week proteinuria endpoint analysis are expected in the first half of 2022. Secondary efficacy endpoints include rate of change in eGFR.

 

 

 

99% Campaign Production Sparsentan Intermediates Cas 254746-77-599% Campaign Production Sparsentan Intermediates Cas 254746-77-5

99% Campaign Production Sparsentan Intermediates Cas 254746-77-599% Campaign Production Sparsentan Intermediates Cas 254746-77-599% Campaign Production Sparsentan Intermediates Cas 254746-77-5

 

99% Campaign Production Sparsentan Intermediates Cas 254746-77-5

 

 

We have complete experimental facilities. And advanced testing instruments ensure the stability of product quality from all aspects. We have a complete sales service system, the products are exported to countries all over the world, and have won a good international reputation with excellent quality and excellent service.Our business is based on honesty and mutual trust. Sincerely look forward to establishing long-term mutually beneficial and good cooperation with customers all over the world.

 

 

Packaging Detail

0.5kgs/Al-Bottle

1.0kgs/Al- Bottle

2.0kgs/Al- Bottle

5.0 kgs/Al-Bottle

25.0 kgs/drum

or upon customers' request.

Storage Store in a well-closed container away from moisture
Shelf Life 2 years if sealed and store away from direct sun light.
Delivery Detail within 3 days after get the payment

Contact Details
Weifang Ruze New Material Co., Ltd.

Contact Person: Ma

Tel: 86-13583611556

Send your inquiry directly to us (0 / 3000)